MAPT and dementia: Previous evidence suggests presence of two peaks of astrocyte reactivity, with an early peak during presymptomatic or prodromal stages that may affect amyloid positivity, followed by a second peak in advanced AD dementia that contributes to neurotoxic effects, tau spreading and cognitive decline.105